Data from phase 2b study, using zelnecirnon for the treatment of patients with atopic dermatitis, is expected in Q3 of 2024; Potential for FDA clinical hold to be removed. The global atopic dermatitis market is expected to reach a valuation of $19.49 billion by the end of 2034. Preliminary ORR data established shows that tivumecirnon might ultimately be effective in treating CPI-naive NSCLC and...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.